Skip to main content
SP5007,631.47-0.71%DOW52,766.88-0.79%NASDAQ26,099.77-1.03%BTC$76,632.00-1.75%ETH$2,376.39-2.83%GOLD$4,384.40-0.27%OIL$89.72-0.55%
Smart Investors Daily
Bio-Rad Laboratories, Inc. logo

NYSE · BIO

Bio-Rad Laboratories, Inc.

Healthcare · Medical - Devices

$380.96

Down-$5.16 (-1.34%)

Updated Sep 2, 2026, 12:48 PM

SID Score

6.1/10

Composite research score

Smart Money

58/100

Neutral

Market cap
8.47B
P/E ratio
-12.51
Dividend yield
0.00%
52-week range
$236.73 – $396.23
Volume
256.11K
Avg. volume
214.04K

Price performance

BIO price history

1M range · 21 trading sessions · Daily adjusted prices

BIO closed at $380.96 after 21 trading sessions, up 14.44% for the selected period.

Last close
$380.96
Period change
+14.44%
Period low
$332.88
Period high
$390.34
Daily close
View OHLC price history
BIO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 1, 2026$387.88$387.88$380.27$380.96256.11K
Aug 31, 2026$393.85$394.02$382.13$386.12301.42K
Aug 28, 2026$390.82$392.29$382.102$387.70206.97K
Aug 27, 2026$389.03$396.23$386.69$389.94245.88K
Aug 26, 2026$393.10$393.10$385.50$388.64221.66K
Aug 25, 2026$384.00$390.83$377.80$390.34295.72K
Aug 24, 2026$384.09$384.09$373.40$381.76300.15K
Aug 21, 2026$385.80$385.92$373.4697$380.03341.18K
Aug 20, 2026$360.29$380.71$360.25$376.46337.56K
Aug 19, 2026$356.89$367.95$352.70$364.26257.99K
Aug 18, 2026$356.17$356.485$351.8013$352.69210.66K
Aug 17, 2026$359.29$359.29$353.86$355.23213.51K
Aug 14, 2026$361.06$362.49$355.07$356.26173.82K
Aug 13, 2026$364.00$365.00$352.12$361.19207.47K
Aug 12, 2026$353.06$362.42$351.00$362.08233.89K
Aug 11, 2026$349.37$358.69$349.37$356.25251.92K
Aug 10, 2026$350.49$355.85$347.86$354.54221.11K
Aug 7, 2026$339.18$353.33$339.18$352.47266.85K
Aug 6, 2026$345.05$345.05$336.09$342.43305.01K
Aug 5, 2026$340.00$352.63$329.60$347.86522.12K
Aug 4, 2026$336.52$338.415$325.31$332.88274.33K

Latest BIO news

The latest Smart Investors Daily articles mentioning BIO.

Stock researchCompany · Overview

BIO research

Overview

Company profile and research snapshot.

Company profile

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$340.00
Implied upside
—
Analysts
—
BIO recent ratings
DateFirmRatingTarget
Aug 7, 2026RBC CapitalOutperform—
Aug 5, 2026Wells FargoEqual-Weight—
Aug 5, 2026RBC CapitalOutperform—
Aug 5, 2026CitigroupNeutral—
May 15, 2026RBC CapitalOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 23, 2026

Microfluidics Research Report 2026-2035: A $20.73 Billion Market by 2030 with Thermo Fisher Scientific, PerkinElmer, Dolomite, Agilent Technologies, Bio-Rad Laboratories, and Fluidigm Leading

The microfluidics market presents significant opportunities in laboratory-on-a-chip research, miniaturized diagnostics, pharmaceutical R&D, and personalized medicine. Growth drivers include advancements in IoT integration, point-of-care diagnostics, and high-throughput screening, with North America leading the expansion. Microfluidics Market Microfluidics Market Dublin, Feb. 23, 2026 (GLOBE NEWSWIRE) -- The "Microfluidics Market Report 2026" has been added to ResearchAndMarkets.com's offering. T

Yahoo · Feb 19, 2026

Bio-Rad Laboratories, Inc. (BIO) Achieves Modest Revenue Growth and Robust Free Cash Flow Growth

Bio-Rad Laboratories, Inc. (NYSE:BIO) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 12, Bio-Rad Laboratories, Inc. (NYSE:BIO) delivered solid fourth-quarter and full-year results despite a challenging year marked by geopolitical uncertainty and continued pressure on academic research. The company delivered modest revenue growth and strong free cash […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By